Health Care & Life Sciences » Pharmaceuticals | Starpharma Holdings Ltd.

Starpharma Holdings Ltd. | Cash Flow

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
14,635.00
18,950.00
22,675.00
8,200.00
10,285.00
Depreciation, Depletion & Amortization
1,096.00
1,221.00
931.00
318.00
311.00
Other Funds
1,444.00
803.00
1,206.00
20,958.00
1,861.00
Funds from Operations
12,095.00
16,926.00
20,538.00
12,440.00
8,113.00
Changes in Working Capital
2,282.00
3,311.00
2,727.00
4,515.00
2,088.00
Net Operating Cash Flow
9,813.00
13,615.00
17,811.00
16,955.00
10,201.00
Capital Expenditures
251.00
653.00
97.00
625.00
359.00
Sale of Fixed Assets & Businesses
-
-
1.00
33,281.00
-
Purchase/Sale of Investments
-
-
125.00
-
-
Net Investing Cash Flow
251.00
653.00
29.00
32,656.00
359.00
Issuance/Reduction of Debt, Net
32.00
32.00
32.00
21.00
-
Net Financing Cash Flow
203.00
20,471.00
32,564.00
21.00
26.00
Net Change in Cash
9,812.00
6,820.00
15,124.00
15,216.00
9,869.00
Free Cash Flow
10,064.00
14,268.00
17,908.00
17,580.00
10,560.00
Change in Capital Stock
235.00
20,503.00
32,596.00
-
-
Exchange Rate Effect
49.00
617.00
342.00
464.00
717.00

About Starpharma Holdings

View Profile
Address
4-6 Southampton Crescent
Abbotsford Victoria (VIC) 3067
Australia
Employees -
Website http://www.starpharma.com
Updated 07/08/2019
Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. Its programs include: VivaGel portfolio, Drug delivery and Agrochemicals, which develops a number of products internally and others via commercial partnerships. Its product is VivaGel, a gel-based formulation of a proprietary dendrimer and is under clinical development for the treatment and prevention of bacterial vaginosis and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes.